Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Angelo Sansonetti et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Luca Bergamaschi et al.|Pharmacological Research|2022Cited by 146
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT studyArturo Cesaro, Raffaele Marfella, Felice Gragnano et al.|Frontiers in Cardiovascular Medicine|2022Cited by 87
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registryPasquale Paolisso, Carmine Pizzi, Luca Bergamaschi et al.|Diabetes Research and Clinical Practice|2023Cited by 77
Echocardiographic Markers in the Diagnosis of Cardiac MassesPasquale Paolisso, Carmine Pizzi, Alberto Foà et al.|Journal of the American Society of Echocardiography|2023Cited by 42